Aclaris Therapeutics (ACRS) Reports Q2 Loss of $0.62/Share

Aclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.62), versus ($1.52) reported last year.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Cerebras Q1 EPS miss sends shares down 9% after-hours